The Long-Term Impact of Biosimilars on Specialty Pharmacy

Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.

Related Content:

InterviewsSpecialty Pharmacy

Study Supports Link Between Inflammation, Cognitive Problems in Older Breast Cancer Survivors

Grant Awarded to Study Some of the Most Fatal Forms of Cancers

Expert Discusses Changes to Drug Supply Chain Security Act